Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?

Breast Cancer Research and Treatment

Volumn 94, Issue 2, 2005, Pages 95-103

  Naeim, Arash ^a   Keeler, Emmett B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RAND CORPORATION   (United States)

Author keywords

Adjuvant treatment; Breast cancer; Chemotherapy; Cost effectiveness; Elderly; Hormone treatment

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DATA ANALYSIS; DRUG COST; DRUG EFFICACY; EARLY CANCER; HUMAN; LIFE TABLE; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SYSTEMATIC REVIEW;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HEALTH SERVICES FOR THE AGED; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, ESTROGEN; UNITED STATES;

EID: 27644448953     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-004-8267-0     Document Type: Article

References (40)

1. SG Diab RM Elledge GM Clark 2001 Response: Re: tumor characteristics and clinical outcome of elderly women with breast cancer J Natl Cancer Inst 93 65 66
2. SG Diab RM Elledge GM Clark 2000 Tumor characteristics and clinical outcome of elderly women with breast cancer J Natl Cancer Inst 92 550 556
3. R Yancik 1997 Cancer burden in the aged: an epidemiologic and demographic overview Cancer 80 1273 1283
4. C Bouchardy E Rapiti G Fioretta P Laissue I Neyroud-Caspar P Schafer J Kurtz AP Sappino G Vlastos 2003 Undertreatment strongly decreases prognosis of breast cancer in elderly women J Clin Oncol 21 3580 3587
5. Muss HB: Factors used to select adjuvant therapy of breast cancer in the United States: an overview of age, race, and socioeconomic status J Natl Cancer Inst Monogr 52-55, 2001
6. RW Carlson BO Anderson W Bensinger CE Cox NE Davidson SB Edge WB Farrar LJ Goldstein WJ Gradishar AS Lichter B [tmp] McCormick LM Nabell EC Reed SM Silver ML Smith G Somlo R Theriault JH Ward EP Winer A Wolff 2000 NCCN practice guidelines for breast cancer Oncology (Huntingt) 14 33 49
7. RW Carlson SB Edge RL Theriault 2001 NCCN: breast cancer Cancer Control 8 54 61
8. MS Aapro 2001 Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001 Oncologist 6 376 385
9. B Fisher 1969 Systemic chemotherapy as an adjuvant to surgery in the treatment of breast cancer Cancer 24 1286 1289
10. EBCTCG 1988 Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group N Engl J Med 319 1681 1692
11. EBCTCG 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women Lancet 339 71 85
12. EBCTCG 1998 Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group Lancet 351 1451 1467
13. EBCTCG 1998 Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group Lancet 352 930 942
14. NIH Consensus Statement on Adjuvant Therapy for Breast Cancer. In: 2000 NIH Consensus Conference on Adjuvant Breast cancer, 2000, pp 1-35.
15. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 5-15, 2001.
16. JS Abrams 2001 Adjuvant therapy for breast cancer - results from the USA consensus conference Breast Cancer 8 298 304
17. BE Hillner TJ Smith 1991 Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model N Engl J Med 324 160 168
18. BE Hillner TJ Smith CE Desch 1993 Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model Breast Cancer Res Treat 25 97 105
19. BE Hillner 1993 Financial costs, benefits, and patient risk preferences in node-negative breast cancer: insights from a decision analysis model Recent Results Cancer Res 127 277 284
20. CE Desch BE Hillner TJ Smith SM Retchin 1993 Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes J Clin Oncol 11 777 782
21. A Messori P Becagli S Trippoli E Tendi 1996 Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer Eur J Clin Pharmacol 51 111 116
22. NCHS: United States Life Tables, 1999. In: National Center for Health Statistics, 1999
23. A Naeim EB Keeler 2005 Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective Crit Rev Oncol Hematol 53 81 89
24. H Kattlove A Liberati E Keeler RH Brook 1995 Benefits and costs of screening and treatment for early breast cancer. Development of a basic benefit package JAMA 273 142 148
25. Malin J, Keeler E: Cost-effectiveness and health benefit of breast cancer in women with early breast cancer. In: RAND, Los Angeles, 2000, p 28
26. CA Quiet DJ Ferguson RR Weichselbaum S Hellman 1996 Natural history of node-positive breast cancer: the curability of small cancers with a limited number of positive nodes J Clin Oncol 14 3105 3111
27. BE Hillner TJ Smith 1995 Cost effectiveness and other assessments of adjuvant therapies for early breast cancer Oncology (Huntingt) 9 129 134
28. JH Silber M Fridman A Shpilsky O Even-Shoshan DS Smink J Jayaraman KR Fox MV Pauly 1998 Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer J Clin Oncol 16 2435 2444
29. B Fisher AM Brown NV Dimitrov R Poisson C Redmond RG Margolese D Bowman N Wolmark DL Wickerham CG Kardinal 1990 Two months of doxorubicin- cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15 J Clin Oncol 8 1483 1496
30. MR Gold 1996 Cost-Effectiveness in Health and Medicine Oxford University Press New York 425
31. BJ [tmp] McNeil R Weichselbaum SG Pauker 1978 Fallacy of the five-year survival in lung cancer N Engl J Med 299 1397 1401
32. MR Rolison A Scherman 2002 Factors influencing adolescents' decisions to engage in risk-taking behavior Adolescence 37 585 596
33. K Kerlikowske P Salzmann KA Phillips JA Cauley SR Cummings 1999 Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness JAMA 282 2156 2163
34. X Du JS Goodwin 2001 Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data J Clin Oncol 19 1455 1461
35. M Extermann 2002 Comorbidity and geriatric assessment in the elderly patient over the age of 70 Tumori 88 S9
36. M Extermann 2003 Studies of comprehensive geriatric assessment in patients with cancer Cancer Control 10 463 468
37. M Extermann 2004 Management issues for elderly patients with breast cancer Curr Treat Options Oncol 5 161 169
38. JS Mandelblatt WF Lawrence SM Womack D Jacobson B Yi YT Hwang K Gold J Barter K Shah 2002 Benefits and costs of using HPV testing to screen for cervical cancer JAMA 287 2372 2381
39. RP [tmp] McQuellon HB Muss SL Hoffman G Russell B Craven SB Yellen 1995 Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer J Clin Oncol 13 858 868
40. LC Walter KE Covinsky 2001 Cancer screening in elderly patients: a framework for individualized decision making JAMA 285 2750 2756